← Back to screener

AbbVie Inc. ABBV

Rank #1716 · NYSE · $521.0B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
43.7
P/E
107.1
P/B
156.69
ROE
146.3%
Op. Margin
23.5%
Debt Ratio
3965%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E 107.1x, P/B 156.69x. Ranks in the top 78% of the universe.

Profitability ★★★★★
Excellent

ROE 146.3%. Ranks in the top 8% of the universe.

Safety ★☆☆☆☆
Poor

Debt ratio 3965%. Ranks in the top 99% of the universe. Above 200% signals meaningful leverage risk.

Growth ★☆☆☆☆
Weak

Revenue decline of 6.4% year over year. Ranks in the top 79% of the universe.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2013–$3.6B–$-0.3B–-7817
2014–$5.8B–$4.5B–550
2015–$5.7B–$4.5B–512
2016–$3.4B$1.8B$4.5B–1081
2017–$7.5B$5.1B$1.7B–3694
2018$25.6B$9.3B$6.0B$3.9B36.41694
2019$28.2B$9.5B$5.3B$4.6B33.81180
2020$32.8B$6.4B$5.7B$-8.2B19.5-1190
2021$33.3B$13.0B$7.9B$13.1B39.01051
2022$45.8B$11.4B$4.6B$15.4B24.8851
2023$56.2B$17.9B$11.5B$17.3B31.9704
2024$58.1B$18.1B$11.8B$10.4B31.21200
2025$54.3B$12.8B$4.9B$3.3B23.53965

← See the full screener